ARTICLE | Company News
Asklepios, Calimmune deal
February 1, 2016 8:00 AM UTC
Asklepios granted Calimmune rights to Asklepios’ adeno-associated virus (AAV) gene therapy technologies, which Calimmune plans to use in a Phase I/II trial of a gene therapy to treat osteoarthritis. A...